Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Paclitaxel plus Subcutaneous Pertuzumab/Trastuzumab in Neoadjuvant HER2+ Breast Cancer
NCT07095023Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Open-label, single-arm trial of paclitaxel oral solution, pertuzumab and trastuzumab in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Total Pathological Complete Response at 6 months. Started Aug 2025; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07095023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095023.